We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Simple Blood Test Can Identify People with Higher Risk of Stroke

By LabMedica International staff writers
Posted on 13 Aug 2024

Atrial fibrillation is the most prevalent cardiac arrhythmia, affecting approximately one-third of all individuals at some point in their lives. More...

It is a common cause of stroke because it increases the risk of blood clots forming in the heart’s atria. Consequently, many individuals with atrial fibrillation receive anticoagulation therapy to prevent strokes. However, due to the heightened risk of serious hemorrhages from anticoagulation, only those with a moderate or high stroke risk are treated, not everyone with the condition. Therefore, accurately identifying those who would benefit from anticoagulation is crucial. While blood tests are routinely used in healthcare to assess organ function, including the heart, kidneys, and liver, no standard blood test exists to evaluate brain health in relation to cardiovascular disease. Researchers have now shown that a simple blood test reflecting brain health can determine which individuals are at increased stroke risk. This breakthrough could lead to more personalized treatment for patients with atrial fibrillation.

Researchers at Uppsala University (Uppsala, Sweden) studied the neurofilament protein, which is released from the brain under stress or low oxygen conditions, in blood samples from over 3000 individuals with atrial fibrillation. They monitored these individuals for an average of 18 months. Those with the highest levels of neurofilament in their blood were found to face the highest stroke risk. According to findings published in the journal Circulation, the risk of stroke for the quarter with the highest neurofilament levels was more than triple that of those with the lowest levels. Adding neurofilament measurements to standard cardiac blood tests from the same patients further improved stroke prediction. The next research steps will explore how various healthcare treatments affect neurofilament levels and whether this impacts the risk of stroke or death.

“We hope to be able to intervene at an earlier stage and inhibit injurious strain on the brain before it gives rise to symptoms,” said Julia Aulin, a cardiologist at Uppsala University Hospital and researcher at Uppsala University, the lead author of the study. “The findings are probably transferrable to other groups of patients with cardiovascular-related disorders, though this remains to be demonstrated. Our hope is that it will ultimately be possible to assess brain health with a simple blood test at the local health center.”

Related Links:
Uppsala University


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.